Company / Return on Equity (ROE)
Xenon Pharmaceuticals Inc. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-59.5%
FY2025
5-year range
-59.5% / -14.3%
FY2021-FY2025
Trend
-91.6%
vs FY2024
Sector context
#147 of 190
Health Care
What the data says
Xenon Pharmaceuticals Inc. reports negative total equity of -59.5% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-59.5% in FY2025 with a 5-year CAGR of -42.6%.
Declined from -19.7% to -59.5% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -42.1pp
- 5-Year Change
- -42.6pp
- 10-Year Change
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 190This company -59.5% Sector average -50.3%
▼
-18.2% below sector average
Key checks
Key Insights
- Xenon Pharmaceuticals Inc.'s return on equity (roe) has declined for 4 consecutive years.
- In FY2025, return on equity (roe) decreased 91.6% year-over-year.
- Currently 9.1pp below the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.51 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -59.5% | -91.6% |
| FY2024 | -31.0% | -57.9% |
| FY2023 | -19.7% | -13.1% |
| FY2022 | -17.4% | -21.2% |
| FY2021 | -14.3% | +14.8% |
| FY2020 | -16.8% | +62.8% |
| FY2019 | -45.2% | -35.4% |
| FY2018 | -33.4% | -35.5% |
| FY2017 | -24.6% | +31.5% |
| FY2016 | -36.0% | -39.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026